摘要
目的探讨布地奈德福莫特罗治疗慢性阻塞性肺疾病(COPD)的临床疗效,以及对患者痰液中NOD样受体热蛋白结构域相关蛋白3(NLRP3)炎性小体水平的影响。方法选取医院2019年12月至2021年12月收治的COPD患者98例,按随机数字表法分为研究组和对照组,各49例。两组患者均予常规治疗,研究组在此基础上加用布地奈德福莫特罗,均连续治疗3个月。结果研究组患者总有效率为95.92%,显著高于对照组的81.63%(P<0.05)。治疗后,两组患者的用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、FEV_(1)/FVC均显著高于治疗前(P<0.05),残气量(RV)/肺总量(TLC)均显著低于治疗前(P<0.05),且研究组均显著优于对照组(P<0.05);动脉血氧分压(PaO_(2))、血氧饱和度(SpO_(2))均显著高于治疗前(P<0.05),二氧化碳分压(PaCO_(2))均显著低于治疗前(P<0.05),且研究组均显著优于对照组(P<0.05);NLRP3炎性小体、白细胞介素18(IL-18)、白细胞介素1β(IL-1β)水平均显著低于治疗前(P<0.05),且研究组均显著低于对照组(P<0.05)。研究组患者药品不良反应发生率为10.20%,显著低于对照组的28.57%(P<0.05)。结论布地奈德福莫特罗治疗COPD疗效较好,可改善患者的肺功能和动脉血气指标,降低NLRP3炎性小体及炎性因子水平,且安全性良好。
Objective To investigate the clinical efficacy of budesonide and formoterol in the treatment of patients with chronic obstructive pulmonary disease(COPD),and its effect on the NOD-like receptor thermal protein domain-associated protein 3(NLRP3)inflammasome levels in the sputum of patients.Methods A total of 98 patients with COPD admitted to the hospital from December 2019 to December 2021 were selected and divided into the study group and the control group by the random number table method,with 49 cases in each group.The patients in the two groups were given routine treatment,and the patients in the study group were treated with budesonide and fomotoprob on this basis.Both groups were treated for three courses of treatment.Results The total effective rate in the study group was 95.92%,which was significantly higher than 81.63%in the control group(P<0.05).After treatment,the forced vital capacity(FVC),forced expiratory volume in the first second(FEV_(1))and FEV_(1)/FVC in the two groups were significantly higher than those before treatment(P<0.05),while the residual volume(RV)/total lung capacity(TLC)in the two groups were significantly lower than those before treatment(P<0.05),and those in the study group were significantly better than those in the control group(P<0.05);the arterial oxygen partial pressure(PaO_(2))and peripheral oxygen saturation(SpO_(2))in the two groups were significantly higher than those before treatment(P<0.05),while the partial pressure of carbon dioxide(PaCO_(2))in the two groups was significantly lower than those before treatment(P<0.05);and those in the study group were significantly better than those in the control group(P<0.05);the levels of NLRP3 inflammasome,interleukin-18(IL-18),and interleukin-1β(IL-1β)in the two groups were significantly lower than those before treatment(P<0.05),and those in the study group were significantly lower than those in the control group(P<0.05).The incidence of adverse reactions in the study group was 10.20%,which was significantly lower than the 28.57%in the control group(P<0.05).Conclusion Budesonide and formoterol are effective and safe in the treatment of COPD,which can improve pulmonary function and arterial blood gas indexes,and reduce the level of NLRP3 inflammasome and inflammatory factors.
作者
李秀琼
吴智
黄昌秀
LI Xiuqiong;WU Zhi;HUANG Changxiu(Hainan Second People's Hospital,Wuzhishan,Hainan,China 572299)
出处
《中国药业》
CAS
2023年第11期85-88,共4页
China Pharmaceuticals
基金
海南省卫生健康行业科研项目[20A200242]。
